U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06991478) titled 'SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites' on May 18.
Brief Summary: This study is divided into two phases. Patients with recurrent or metastatic solid tumors accompanied by malignant ascites who have failed previous standard treatments are enrolled. The first phase is a single-arm, open-dose exploratory Phase I clinical study. In this phase, two dose groups are preset, namely 20x108 cells and 30x108 cells. Subjects who meet the inclusion criteria will receive intravenous infusion of SK-NK injection. Once a week for 6 consecutive infusions. After completing 6 consecutive infusions of SK-N...